PE20070365A1 - Forma cristalina de n-[2-(7-metoxi-1-naftil)etil]acetamida (agomelatina), su procedimiento de preparacion y las composiciones farmaceuticas que la contienen - Google Patents
Forma cristalina de n-[2-(7-metoxi-1-naftil)etil]acetamida (agomelatina), su procedimiento de preparacion y las composiciones farmaceuticas que la contienenInfo
- Publication number
- PE20070365A1 PE20070365A1 PE2006000868A PE2006000868A PE20070365A1 PE 20070365 A1 PE20070365 A1 PE 20070365A1 PE 2006000868 A PE2006000868 A PE 2006000868A PE 2006000868 A PE2006000868 A PE 2006000868A PE 20070365 A1 PE20070365 A1 PE 20070365A1
- Authority
- PE
- Peru
- Prior art keywords
- agomelatin
- crystalline form
- metoxy
- acetamide
- naphthyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A UNA FORMA CRISTALINA DE N-[2-(7-METOXI-1-NAFTIL)ETIL]ACETAMIDA (AGOMELATINA) QUE TIENE UN DIAGRAMA DE DIFRACCION DE POLVO DE RAYOS X QUE TIENE PICOS CARACTERISTICOS EXPRESADOS EN EL ANGULO 2 DE 9,84; 12,40; 13,31; 15,14; 15,98; 16,62; 17,95; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION QUE CONSISTE EN SOMETER LA AGOMELATINA A UN TRITURADO MECANICO DE ALTA ENERGIA. DICHA FORMA CRISTALINA DE AGOMELATINA ES AGONISTA DE LOS RECEPTORES DEL SISTEMA MELATONINERGICO Y ANTAGONISTA DEL RECEPTOR DE SEROTONINA 5-HT2C SIENDO UTIL EN EL TRATAMIENTO DE ANSIEDAD, DEPRESION, INSOMNIO, ESQUIZOFRENIA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0508278A FR2889523B1 (fr) | 2005-08-03 | 2005-08-03 | Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070365A1 true PE20070365A1 (es) | 2007-06-02 |
Family
ID=36581629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000868A PE20070365A1 (es) | 2005-08-03 | 2006-07-19 | Forma cristalina de n-[2-(7-metoxi-1-naftil)etil]acetamida (agomelatina), su procedimiento de preparacion y las composiciones farmaceuticas que la contienen |
Country Status (38)
Country | Link |
---|---|
EP (2) | EP2277857A3 (es) |
JP (1) | JP4575337B2 (es) |
CN (1) | CN100448843C (es) |
AP (1) | AP2486A (es) |
AR (1) | AR057715A1 (es) |
AU (1) | AU2006203342B2 (es) |
BR (1) | BRPI0603059A (es) |
CA (1) | CA2555115C (es) |
CR (1) | CR8529A (es) |
CU (1) | CU20060153A7 (es) |
CY (1) | CY1113011T1 (es) |
DK (1) | DK1752443T3 (es) |
EA (1) | EA011030B1 (es) |
EC (1) | ECSP066715A (es) |
ES (1) | ES2391406T3 (es) |
FR (1) | FR2889523B1 (es) |
GT (1) | GT200600346A (es) |
HK (1) | HK1098128A1 (es) |
HR (1) | HRP20120779T1 (es) |
IL (1) | IL177173A (es) |
JO (1) | JO2793B1 (es) |
MA (1) | MA28451B1 (es) |
ME (1) | ME02026B (es) |
MX (1) | MXPA06008789A (es) |
MY (1) | MY139902A (es) |
NO (1) | NO336967B1 (es) |
NZ (1) | NZ548864A (es) |
PE (1) | PE20070365A1 (es) |
PL (1) | PL1752443T3 (es) |
PT (1) | PT1752443E (es) |
RS (1) | RS52423B (es) |
SA (1) | SA06270255B1 (es) |
SG (1) | SG130110A1 (es) |
SI (1) | SI1752443T1 (es) |
TW (1) | TWI359128B (es) |
UA (1) | UA83720C2 (es) |
WO (1) | WO2007015004A2 (es) |
ZA (1) | ZA200606453B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2934856B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede d'obtention de la forme cristalline v de l'agomelatine |
CN101481321B (zh) * | 2009-02-27 | 2012-04-18 | 上海医药工业研究院 | 阿戈美拉汀卤化氢复合物及其制备方法 |
CN101585779B (zh) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
WO2011006387A1 (zh) * | 2009-07-11 | 2011-01-20 | 浙江华海药业股份有限公司 | 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法 |
CN102001959B (zh) * | 2009-09-01 | 2014-07-02 | 北京本草天源药物研究院 | 一种药物晶体及其制备方法和用途 |
CN102050755B (zh) * | 2009-10-29 | 2014-11-05 | 重庆医药工业研究院有限责任公司 | 阿戈美拉汀的晶型及其制备方法 |
CN101781226B (zh) * | 2009-12-23 | 2012-03-28 | 天津泰普药品科技发展有限公司 | 阿戈美拉汀及其药物组合物 |
EP2580183B1 (en) | 2010-06-10 | 2014-07-23 | Gador S.A. | New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide |
CN102000583B (zh) * | 2010-11-18 | 2012-08-15 | 烟台万华聚氨酯股份有限公司 | 一种氯化氢氧化制氯气的催化剂及其制备方法 |
CN102690210A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物 |
CN102690209A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 |
CA3094762C (en) * | 2011-06-02 | 2023-09-26 | CHINOIN Zrt. | Novel processes for the preparation of prostaglandin amides |
FR2978916B1 (fr) | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
EP2771312B1 (en) | 2011-11-30 | 2017-05-31 | ratiopharm GmbH | Agomelatine-urea complex and crystalline forms thereof |
CZ2012108A3 (en) | 2012-02-15 | 2013-02-27 | Zentiva Ks | A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine |
CN103360275B (zh) * | 2012-03-30 | 2015-04-22 | 上海创诺制药有限公司 | 一种制备阿戈美拉汀ⅰ型晶体的方法 |
EP2934502A1 (en) | 2012-12-21 | 2015-10-28 | Laboratorios Lesvi S.L. | Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof |
FR3001894A1 (fr) | 2013-02-08 | 2014-08-15 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
EP2810656B1 (en) | 2013-06-06 | 2017-08-02 | Zentiva, a.s. | Agomelatine formulations comprising agomelatine in the form of co-crystals |
EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
CZ2013621A3 (cs) | 2013-08-13 | 2015-02-25 | Zentiva, K.S. | Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci |
WO2015124496A1 (en) | 2014-02-19 | 2015-08-27 | Synthon B.V. | Pharmaceutical composition comprising amorphous agomelatine |
FR3033131B1 (fr) | 2015-02-26 | 2017-11-17 | Servitronique | Glissiere pour ses systemes de reglage coulissants et procede d'assemblage |
ES2959460T3 (es) | 2015-03-31 | 2024-02-26 | Fis Fabbrica Italiana Sintetici Spa | Forma sólida de agomelatina |
EP3466413A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Pharmaceutical composition containing agomelatine and process for the preparation thereof |
EP3466923A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Process for the preparation of agomelatine in crystalline form |
CN113952323A (zh) * | 2021-12-10 | 2022-01-21 | 李甜 | 阿戈美拉汀在抑制Ube2c蛋白表达中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2866336B1 (fr) * | 2004-02-13 | 2006-03-24 | Servier Lab | Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine |
FR2866335B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
-
2005
- 2005-08-03 FR FR0508278A patent/FR2889523B1/fr not_active Expired - Fee Related
-
2006
- 2006-07-19 PE PE2006000868A patent/PE20070365A1/es not_active Application Discontinuation
- 2006-07-20 EC EC2006006715A patent/ECSP066715A/es unknown
- 2006-07-24 JO JO2006247A patent/JO2793B1/en active
- 2006-07-24 MA MA29212A patent/MA28451B1/fr unknown
- 2006-07-24 CR CR8529A patent/CR8529A/es unknown
- 2006-07-24 AP AP2006003695A patent/AP2486A/xx active
- 2006-07-31 IL IL177173A patent/IL177173A/en active IP Right Grant
- 2006-07-31 GT GT200600346A patent/GT200600346A/es unknown
- 2006-08-01 SA SA06270255A patent/SA06270255B1/ar unknown
- 2006-08-01 SG SG200605171-8A patent/SG130110A1/en unknown
- 2006-08-01 NZ NZ548864A patent/NZ548864A/en not_active IP Right Cessation
- 2006-08-02 UA UAA200608689A patent/UA83720C2/ru unknown
- 2006-08-02 EP EP10011469A patent/EP2277857A3/fr not_active Withdrawn
- 2006-08-02 MY MYPI20063736A patent/MY139902A/en unknown
- 2006-08-02 SI SI200631396T patent/SI1752443T1/sl unknown
- 2006-08-02 RS RS20120327A patent/RS52423B/en unknown
- 2006-08-02 AR ARP060103366A patent/AR057715A1/es not_active Application Discontinuation
- 2006-08-02 BR BRPI0603059-9A patent/BRPI0603059A/pt not_active Application Discontinuation
- 2006-08-02 WO PCT/FR2006/001869 patent/WO2007015004A2/fr active Application Filing
- 2006-08-02 EA EA200601273A patent/EA011030B1/ru unknown
- 2006-08-02 PL PL06291251T patent/PL1752443T3/pl unknown
- 2006-08-02 TW TW095128302A patent/TWI359128B/zh not_active IP Right Cessation
- 2006-08-02 PT PT06291251T patent/PT1752443E/pt unknown
- 2006-08-02 ME MEP-2012-327A patent/ME02026B/me unknown
- 2006-08-02 CU CU20060153A patent/CU20060153A7/es unknown
- 2006-08-02 EP EP06291251A patent/EP1752443B1/fr active Active
- 2006-08-02 ES ES06291251T patent/ES2391406T3/es active Active
- 2006-08-02 NO NO20063517A patent/NO336967B1/no unknown
- 2006-08-02 DK DK06291251.4T patent/DK1752443T3/da active
- 2006-08-03 JP JP2006211622A patent/JP4575337B2/ja not_active Expired - Fee Related
- 2006-08-03 MX MXPA06008789A patent/MXPA06008789A/es active IP Right Grant
- 2006-08-03 ZA ZA200606453A patent/ZA200606453B/en unknown
- 2006-08-03 AU AU2006203342A patent/AU2006203342B2/en not_active Ceased
- 2006-08-03 CN CNB2006101083952A patent/CN100448843C/zh not_active Expired - Fee Related
- 2006-08-03 CA CA2555115A patent/CA2555115C/fr active Active
-
2007
- 2007-04-30 HK HK07104583.8A patent/HK1098128A1/xx not_active IP Right Cessation
-
2012
- 2012-07-18 CY CY20121100635T patent/CY1113011T1/el unknown
- 2012-10-01 HR HRP20120779TT patent/HRP20120779T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070365A1 (es) | Forma cristalina de n-[2-(7-metoxi-1-naftil)etil]acetamida (agomelatina), su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
CR8881A (es) | Compuestos heteroaril- y fenilsulfamoilo sustituidos | |
PE20061142A1 (es) | Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen | |
PE20080186A1 (es) | Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2 | |
CL2007002867A1 (es) | Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras. | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
PE20040650A1 (es) | Moduladores del receptor de glucocorticoides | |
AR068369A1 (es) | Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina" | |
CL2011000301A1 (es) | Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer. | |
AR067701A1 (es) | Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2 | |
AR057714A1 (es) | Nueva forma cristalina iv de la agomelatina, un procedimiento para su preparacion, y las composiciones farmaceuticas que la contienen | |
CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
CL2011001830A1 (es) | Forma cristalina del hidrocloruro de n-[(1s)-2-amino-1-[(3-fluorofenil)metil]etil]-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida; composicion farmaceutica; combinacion farmaceutica; proceso para preparar la composicion farmaceutica; y su uso para tratar o disminuir una enfermedad seleccionada de cancer y artritis. | |
ECSP088106A (es) | Formas de dosificación de liberación retardada oral altamente biodisponible del succinato de o-desmetilvenlafaxina | |
CL2008001465A1 (es) | Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer. | |
CL2008001818A1 (es) | Ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acético amorfo y sus formas cristalinas i y ii; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras. | |
UY30048A1 (es) | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
CL2008001670A1 (es) | Compuestos derivados de piperidina o piperazina, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; y uso para la prevencion o tratamiento de enfermedades tales como obesidad, hipercolesterolemia, dislipidemia, entre otras. | |
PE20160846A1 (es) | Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c | |
RU2009148576A (ru) | Экструдаты с улучшенной маскировкой вкуса | |
AR062114A1 (es) | Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos. | |
BR112013014033A2 (pt) | composição de limpeza e método de intensificação de reologia similar a sabão e impressão similar a sabão de uma composição | |
CL2010001471A1 (es) | Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades.. | |
PE20080941A1 (es) | Compuestos triciclicos como agonistas del receptor de melatonina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |